The Use of EIDD-1931 and Molnupiravir in the Treatment of FIP

This webinar will discuss the mechanism of action and current use of the second-line antiviral EIDD-1931 and it’s prodrug Molnupiravir, for the treatment of feline infectious peritonitis. Particularly cases that have failed GS-441524 therapy. Drs Coggins and Kennedy will share pragmatic and actionable information for US-based clinicians on how to incorporate these antivirals into treatment protocols. What side-effects to monitor for and the expected response to therapy.

1. Gain insight into the pharmacodynamics and antiviral mechanisms of EIDD-1931 and its prodrug, Molnupiravir
2. Learn how to incorporate EIDD-1931 and Molnupiravir into FIP treatment protocols
3. Recognize and monitor for potential adverse side effects of EIDD-1931 and Molnupiravir

Dr. Sally Coggins graduated from The University of Sydney, Australia in 2007 and has been a feline-only clinician since 2010. She attained memberships in feline medicine with the ANZCVS in 2012, was a director at The Cat Clinic Melbourne, an examiner with the ANZCVS, and tutors for the Centre for Veterinary Education. Since 2020, Sally has been completing a PhD investigating antiviral therapies for FIP, where she conducted a national prospective study utilizing remdesivir and GS-441524; characterized the in vitro and in vivo pharmacokinetics of remdesivir in cats with FIP; co-authored a retrospective collaborative study assessing treatment outcomes of 307 cats treated with remdesivir and GS-441524 and has ongoing research collaboration with the US, UK, Germany and New Zealand. Sally also continues to practice clinically one day a week at Evervet in Melbourne, Australia. 

Dr. Alex Kennedy graduated from Sydney University in 2017 and initially worked in general practice in the Hunter region before commencing a rotating internship at SASH in 2019. During this internship Alex undertook a research project evaluating risk factors for feline ureteral obstruction.  She then commenced a specialty internship in internal medicine during which she attained her Memberships with the Australian & New Zealand College of Veterinary Scientists in Small Animal Medicine. Alex then completed an ACVIM residency program for three years, before becoming a Diplomate in Small Animal Internal Medicine mid 2024. She enjoys all aspects of internal medicine, but is particularly interested in interventional procedures.